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THE WOMEN’S HEALTH INITIA-tive (WHI) Dietary Modifica-tion Trial is a randomizedcontrolled trial designed in
1991-1992 to test whether a low-fat eat-
ing pattern with increased fruits, veg- etables, and grains reduces the risk of
breast cancer, colorectal cancer, or, sec-
ondarily, coronary heart disease in post-
menopausal women. At that time, inter-See also pp 629 and 655.
Author Affiliations are listed at the end of this
article.
Corresponding Author: Shirley A. A. Beresford, PhD,
Department of Epidemiology, University ofWashing-
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Context Observational studies and polyp recurrence trials are not conclusive regard-
ing the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a
primary prevention trial.
Objective To evaluate the effects of a low-fat eating pattern on risk of colorectal
cancer in postmenopausal women.
Design, Setting, and Participants The Women’s Health Initiative Dietary Modi-
fication Trial, a randomized controlled trial conducted in 48835 postmenopausal women
aged 50 to 79 years recruited between 1993 and 1998 from 40 clinical centers through-
out the United States.
Interventions Participants were randomly assigned to the dietary modification
intervention (n=19541; 40%) or the comparison group (n=29294; 60%).The inten-
sive behavioral modification program aimed to motivate and support reductions in
dietary fat, to increase consumption of vegetables and fruits, and to increase grain
servings by using group sessions, self-monitoring techniques, and other tailored and
targeted strategies. Women in the comparison group continued their usual eating
pattern.
Main Outcome Measure Invasive colorectal cancer incidence.
Results A total of 480 incident cases of invasive colorectal cancer occurred during a
mean follow-up of 8.1 (SD, 1.7) years. Intervention group participants significantly
reduced their percentage of energy from fat by 10.7%more than did the comparison
group at 1 year, and this difference between groups was mostly maintained (8.1% at
year 6). Statistically significant increases in vegetable, fruit, and grain servings were
also made. Despite these dietary changes, there was no evidence that the interven-
tion reduced the risk of invasive colorectal cancer during the follow-up period. There
were 201 women with invasive colorectal cancer (0.13% per year) in the intervention
group and 279 (0.12% per year) in the comparison group (hazard ratio, 1.08; 95%
confidence interval, 0.90-1.29). Secondary analyses suggested potential interactions
with baseline aspirin use and combined estrogen-progestin use status (P=.01 for each).
Colorectal examination rates, although not protocol defined, were comparable be-
tween the intervention and comparison groups. Similar results were seen in analyses
adjusting for adherence to the intervention.
Conclusion In this study, a low-fat dietary pattern intervention did not reduce the
risk of colorectal cancer in postmenopausal women during 8.1 years of follow-up.
Clinical Trials Registration ClinicalTrials.gov Identifier NCT00000611
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national comparisons suggested that
countries with 50% lower fat intake than
the US population had approximately
one third the risk of colorectal can-
cer.1,2 Migration studies supported this
hypothesis. Women migrating from
countries with low fat consumption to
countries with high fat consumption
experienced the higher colorectal can-
cer rates of their new country.3,4 Fairly
consistent evidence existed for an effect
of dietary fat, vegetables and fruits, and
grains on colorectal cancer risk from
within-country observational stud-
ies,2,5-8 although the protective effect of
lower fat intake was no longer clear after
adjusting for energy intake.2,9 The WHI
DietaryModificationTrial is the first ran-
domized trial to directly address the
health effects of a low-fat eating pattern
in predominantly healthy postmeno-
pausal women from diverse racial/
ethnic, geographic, and socioeconomic
backgrounds. This article reports the
principal results for colorectal cancer.
METHODS
Study Population
Recruitment of postmenopausal women
aged 50 to 79 years who were inter-
ested in 1 or more components of the
clinical trials was conducted by 40 clini-
cal centers throughout the United
States.
Recruitment was typically by direct
mail from purchased lists,10 enhanced
by advertising and other community
promotion. Details of the study design
and recruitment have been published
previously.10-12 Eligibility criteria for the
dietary modification trial included will-
ingness to be randomized to an inter-
vention or comparison group and hav-
ing a fat intake at baseline of 32% or
more of total calories as evaluated by
the WHI food frequency question-
naire.13 Major exclusions made at
screening included women with any
prior colorectal cancer or breast can-
cer, other cancers in the last 10 years,
type 1 diabetes, medical conditions with
predicted survival of less than 3 years,
or adherence concerns, including hav-
ing meals frequently prepared away
from home.
Between 1993 and 1998, 48 835 eli-
gible women were randomly assigned
to an intervention or a comparison
group in the ratio of 2:3 for cost-
efficiency (FIGURE 1). Randomization
was based on a permuted-block algo-
rithm with block sizes of 5, 10, or 15
and stratified by clinical center and age
group (50-54, 55-59, 60-69, and 70-74
years).14 All women provided written
informed consent at baseline, as ap-
proved by institutional review boards.
Of the women randomized into this
trial, 16% were simultaneously ran-
domized into 1 of the arms of the hor-
mone therapy trial (conjugated equine
estrogen trial or estrogen-plus-
progestin trial)11 and 25 210 were sub-
sequently randomized into a trial of cal-
cium and vitamin D supplementation.14
Intervention
The intervention was designed to pro-
mote dietary change with the goals of
reducing total fat to 20% of energy in-
take, increasing vegetables and fruits to
at least 5 servings daily and grains to
at least 6 servings daily.15,16 We refer to
this as a low-fat eating pattern. The in-
tervention did not include total en-
ergy reduction or weight loss goals. Al-
though not a separate focus of the
intervention, it was anticipated that by
reducing fat to 20% of energy intake,
saturated fat would also be reduced (7%
energy intake). The intervention was an
intensive behavioral modification pro-
gram, using 18 group sessions in the
first year and quarterly sessions there-
after, led by specially trained and cer-
tified nutritionists.15 Each participant
was given her own dietary fat-gram goal
according to her height. The interven-
tion emphasized self-monitoring tech-
niques and introduced other tailored
and targeted strategies, such as moti-
vational interviewing,17 to lower fat in-
take throughout the intervention pe-
riod. Comparison group participants
received a copy of the US Department
of Health and Human Services’ Di-
Figure 1. Participant Flow in the Dietary Modification Component of the Women’s Health
Initiative
373 092 Women Initiated Screening by Providing
the Eligibility Screening Form
56 139 Provided Consent and Met the ≥32%
Energy From Fat Eligibility Criterion
19 541 Were Assigned to Receive Low-Fat Diet 29 294 Were Assigned to Receive Usual Diet
316 953 Excluded
24 473 Refused Consent
107 210 Had <32% Energy From Fat
185 270 Consent Information Not
Available
48 835 Randomized
7304 Excluded∗
1668 Nutritionist Judgment/Participant
Reevaluation
278 Ate ≥10 Meals per Week Away
From Home
2163 Administrative Ineligibility
229 Had History of Breast Cancer
453 Other Medical Condition
19 541 Included in Primary Analysis 29 294 Included in Primary Analysis
Status on 3/31/05
17 674 Alive and Outcomes Data Submitted
in Last 18 mo
663 Withdrew
254 Lost to Follow-up
950 Deceased
Status on 3/31/05
26 677 Alive and Outcomes Data Submitted
in Last 18 mo
890 Withdrew
273 Lost to Follow-up
1454 Deceased
*Categories are presented for which exclusions are known. More than 1 reason could be given for exclusion.
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etary Guidelines for Americans18 and
other health-related materials but were
not asked to make dietary changes.
Evaluation Procedures
Dietary intake was monitored using the
WHI food frequency questionnaire at
1 year13 and in a rotating one-third
subsample every year thereafter. Re-
ported values after year 1 are based on
the 3-year intervals in which all par-
ticipants were assessed. At baseline, all
women completed a 4-day food rec-
ord after receiving instruction in keep-
ing food records. Nutrition staff at each
clinical center checked each record for
completeness. The records of women
who developed colorectal cancer were
analyzed in a case-case design to con-
trast intervention and comparison cases
according to baseline dietary intake.
Fasting blood specimens were ob-
tained at baseline, at the first annual fol-
low-up, and in a 5.8% subsample
(n=2816) at years 3 and 6 and were cen-
trally stored at −70°C. Biomarkers of di-
etary change (plasma total cholesterol,
plasma triglycerides, serum -tocoph-
erol and serum total carotenoids [- and
-carotene, -cryptoxanthin, zeaxan-
thin, and lutein]) were measured in base-
line and year 3 specimens from the 5.8%
subsample after excluding participants
experiencing a trial end point during the
previous year.
Women completed a medical up-
date questionnaire every 6 months, and
medical records were sought for all
women reporting colorectal cancer. Lo-
cally trained, blinded physician adjudi-
cators reviewed medical records and pa-
thology reports from the self-reported
colorectal cancer cases (available for
97%). Colorectal cancer was con-
firmed by blinded central adjudicators
and coded using the 1992 Surveillance,
Epidemiology, and End Results sys-
tem.19 In all clinical centers, study per-
sonnel involved in delivery of the di-
etary intervention were not part of
outcomes ascertainment or adjudication.
The medical update also monitored
the frequencies of bowel examina-
tions and incident intestinal polyps or
adenomas. Frequency of bowel exami-
Table 1. Baseline Participant Characteristics Pertinent to Colorectal Cancer Risk
Characteristics
No. (%) of Participants*
P
Value†
Intervention
(n = 19 541)
Comparison
(n = 29 294)
Age, y
50-59 7206 (36.9) 10 797 (36.9)
60-69 9086 (46.5) 13 626 (46.5) .99
70-79 3249 (16.6) 4871 (16.6)
Race/ethnicity
White 15 869 (81.2) 23 890 (81.6)
Black 2137 (10.9) 3129 (10.7)
Hispanic 755 (3.9) 1099 (3.8)
.76
American Indian 88 (0.5) 115 (0.4)
Asian/Pacific Islander 433 (2.2) 674 (2.3)
Unknown 259 (1.3) 387 (1.3)
Education
Up to high school diploma/GED 4267 (21.0) 6466 (22.3)
School after high school 7711 (39.7) 11 597 (39.8) .65
College degree or higher 7445 (38.3) 11 042 (37.9)
First-degree relatives with colorectal cancer
0 14 968 (86.2) 22 458 (86.3)
.63
1 2400 (13.8) 3552 (13.7)
History of polyp removal
No 15 726 (91.5) 23 567 (91.6)
.90
Yes 1453 (8.5) 2168 (8.4)
Colonoscopy history at baseline
None 8834 (50.7) 13 176 (50.5)
5 y ago 5338 (30.7) 7872 (30.2) .21
5 y ago 3240 (18.6) 5021 (19.3)
Alcohol use at baseline
Never drinker 1888 (9.7) 2875 (9.9)
Past drinker 3553 (18.3) 5347 (18.4)
.89
1 drink/d 12 058 (62.2) 18 116 (62.2)
1 drink/d 1881 (9.7) 2769 (9.5)
Aspirin dosage at baseline (minimum duration,
14 d), mg/d
None 15 956 (81.7) 23 658 (80.8)
325 807 (4.1) 1319 (4.5) .03
325 2777 (14.2) 4317 (14.7)
Aspirin use duration at baseline
(minimum dosage, 75 mg/d), y
Nonuser 15 956 (81.7) 23 658 (80.8)
1 700 (3.6) 1119 (3.8)
.01
1-8 1981 (10.1) 3110 (10.7)
8 903 (4.6) 1407 (4.8)
Randomized to WHI EP
or estrogen-alone studies
No 16 359 (83.7) 24 426 (83.4)
Estrogen-alone active group 615 (3.2) 1039 (3.6)
Estrogen-alone placebo group 670 (3.4) 1068 (3.7) .05
EP active group 972 (5.0) 1457 (5.0)
EP placebo group 925 (4.7) 1304 (4.5)
Randomized to WHI CaD study
No 9896 (50.6) 13 729 (46.9)
CaD active group 4878 (25.0) 7738 (26.4) .001
CaD placebo group 4767 (24.4) 7827 (26.7)
(continued)
LOW-FAT DIETARY PATTERN AND RISK OF COLORECTAL CANCER
©2006 American Medical Association. All rights reserved. (Reprinted) JAMA, February 8, 2006—Vol 295, No. 6 645
Downloaded From: https://jamanetwork.com/ by a University of California - San Diego User  on 07/01/2019
nations was not dictated by the WHI
protocol. Decisions regarding screen-
ing and diagnostic workups for colo-
rectal cancer were made by the wom-
en’s personal physicians.
Definitions of Outcomes
and Subgroups
The primary study outcome was inva-
sive colorectal cancer incidence; sub-
classifications of colorectal cancer were
secondary outcomes. These include
groupings within the intestinal tract of
distinct etiology20; namely, invasive can-
cer of the proximal colon (cecum, as-
cending colon, hepatic flexure of co-
lon, transverse colon, splenic flexure),
of the distal colon (descending colon,
sigmoid colon),21-23 and of the rectum,
including rectosigmoid junction.24 Re-
sults are also presented for total cancer
incidence, total cancer mortality, total
mortality, and a global index to pro-
vide a context for the colorectal cancer
results. Throughout the trial, a global in-
dex end point was monitored. This con-
sisted of the first to occur of invasive
breast cancer, colorectal cancer, coro-
nary heart disease, or death from other
causes. The intervention effects on breast
cancer and cardiovascular disease are re-
ported separately.25,26
Potential interactions were ex-
plored in subgroups of participants
identified prior to analysis. These were
baseline health characteristics known
to influence colorectal cancer risk and
baseline dietary patterns. Two post hoc
interactions were also examined with
composite variables of baseline hor-
mone therapy use and assignment to the
active treatment group in the hor-
mone therapy trial.
Statistical Analysis
The protocol-designated analysis to
evaluate the efficacy of the low-fat eat-
ing pattern intervention was a
weighted log-rank test, with weights
defined by time since randomization
as 0 at randomization rising linearly to
1 at 10 years of follow-up, and con-
stant (at 1) thereafter. Design assump-
tions included a linear dependence of
colorectal cancer risk on percentage of
energy from fat, with 80% lower colo-
rectal cancer incidence for a 20%-
compared with a 40%-energy-from-fat
diet (from observational studies2,5,9).
Information from the Women’s Health
Trial27 suggested that women in the
intervention group would consume a
13% lower percentage of energy from
fat in the intervention compared with
the comparison group at 1 year, which
was projected to decrease linearly to
an 11% difference by 10 years. With a
sample size of 48 000 women, the
study had 90% power to detect a 20%
relative reduction in colorectal cancer
incidence over a mean 9 years of
follow-up.11
Intervention effects on incidence
rates were assessed using time-to-
event methods based on the intention-
to-treat principle. Women without the
diagnosis were censored for that event
at the time of their last follow-up con-
tact. Comparisons of rates of colorec-
tal cancer (intervention effects) are pre-
sented as hazard ratios (HRs) and
nominal 95% confidence intervals (95%
CIs) from Cox regression models, strati-
fied by age, prior colorectal cancer, and
randomization status in the hormone
therapy trial. Although history of co-
lorectal cancer was an exclusion crite-
rion, after randomization, 16 women
were found to have reported prior co-
lorectal cancer. Consistent with the in-
tention-to-treat principle, these women
were included as a separate stratum in
the Cox models, but these women re-
ported no further diagnoses of colorec-
tal cancer. Adjustment for participa-
tion in the calcium and vitamin D trial
was based on the randomization date
as a time-dependent covariate. Cumu-
lative disease rates over time were es-
timated using the Kaplan-Meier
method. Annualized incidence rates
were calculated as the ratio of number
of events to total person-years of follow-
up. Since colon cancer has a long pre-
clinical phase,28 perhaps as long as 10
years, analyses exploring variation in
intervention effect by period of fol-
low-up were conducted by classifying
events into early (0-24 months), middle
(25-60 months), and late (61 months)
follow-up. A test for trend with time was
used to assess departure from nonpro-
portional effects.
Tests for interactions were per-
formed as likelihood ratio tests in ex-
Table 1. Baseline Participant Characteristics Pertinent to Colorectal Cancer Risk (cont)
Characteristics
No. (%) of Participants*
P
Value†
Intervention
(n = 19 541)
Comparison
(n = 29 294)
Mean (SD) Mean (SD)
Food frequency questionnaire
Total energy, kcal/d 1790.2 (710.1) 1789.4 (703.0) .90
Daily energy from fat, % 37.8 (5.1) 37.8 (5.0) .84
Daily energy from saturated fat, % 12.7 (2.5) 12.7 (2.5) .54
Dietary fiber, g/d 15.4 (6.4) 15.4 (6.4) .63
Red meat, medium servings/d 0.9 (0.6) 0.9 (0.6) .65
Combined fruits/vegetables, medium servings/d 3.6 (1.8) 3.6 (1.8) .52
Grains, medium servings/d 4.7 (2.5) 4.8 (2.5) .33
Total calcium intake from food frequency
questionnaire and dietary supplements, mg/d
1123.7 (686.8)‡ 1117.5 (662.9) .33
Total dietary folate equivalent from food frequency
questionnaire and dietary supplements, µg/d
541.6 (421.1)‡ 541.2 (423.4) .93
Total carotenoids (alpha carotene, beta carotene,
beta cryptoxanthin, lutein, and zeaxanthin),
µg/mL per d
0.68 (0.42)§ 0.67 (0.42)|| .40
Abbreviations: CaD, calcium and vitamin D; EP, estrogen plus progestin; GED, general equivalency diploma; WHI,
Women’s Health Initiative.
*Percentages may not sum to 100% because of rounding error.
†Test of association from 2 test (categorical variables) or t test (continuous variables), excluding categories of missing
values.
‡n = 19 469.
§n = 1068.
||n = 1662.
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panded Cox models. Continuous vari-
ables were tested on the original linear
scale but are described with relevant cat-
egories. Subgroups using baseline di-
etary factors obtained from 4-day food
records were analyzed using a case-
only approach,29,30 essentially equiva-
lent to a test that would arise from a “full-
cohort” analysis of interaction. Because
about 23 interactions were tested, at least
1 significant test would be expected to
occur by chance at the .05 level of
significance.
We examined the extent to which the
intervention was associated with change
Figure 2. Differences in Mean Dietary Intake Between Intervention and Comparison Groups for Each Year of Follow-up
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Table 2. Percentage Changes From Baseline to Year 3 for Dietary Factors and Selected Biomarkers Related to Colorectal
Cancer Risk*
Risk Factors
Baseline, Mean (SD) Year 3, Mean (SD)
Change at Year 3, %
Intervention Comparison Intervention Comparison
Intervention,
Mean (SD)
Comparison,
Mean (SD)
Difference, Mean (95%
Confidence Interval)
Dietary Factors
Total energy, kcal/d 1790.2 (710.1) 1789.4 (703.0) 1495.9 (546.1) 1581.9 (647.5) −10.0 (33.6) −6.0 (35.1) −4.1 (−5.6 to −2.5)†
Fiber, g/d 15.4 (6.4) 15.4 (6.4) 17.9 (7.7) 14.8 (6.5) 25.8 (60.7) 1.9 (44.4) 23.8 (21.6 to 26.1)†
Daily energy from fat, % 37.8 (5.1) 37.8 (5.0) 26.7 (7.9) 36.2 (7.1) −28.6 (20.7) −3.2 (18.5) −25.4 (−26.3 to −24.5)†
Daily energy from saturated fat, % 12.7 (2.5) 12.7 (2.5) 8.8 (3.0) 12.1 (3.0) −28.9 (24.8) −2.4 (23.1) −26.4 (−27.5 to −25.4)†
Servings/d
Red meat 0.9 (0.6) 0.9 (0.6) 0.6 (0.4) 0.8 (0.6) −9.7 (128.4) 10.5 (114.1) −20.2 (−25.5 to −14.8)†
Fish 0.3 (0.3) 0.3 (0.2) 0.3 (0.2) 0.3 (0.2) 39.3 (175.8) 43.2 (218.8) −3.9 (−13.1 to 5.2)
Poultry 0.4 (0.3) 0.4 (0.3) 0.4 (0.3) 0.4 (0.3) 25.6 (151.9) 23.3 (166.4) 2.3 (−4.9 to 9.5)
Vegetables and fruits 3.6 (1.8) 3.6 (1.8) 5.2 (2.5) 3.9 (2.0) 67.7 (134.1) 20.3 (89.2) 47.4 (42.5 to 52.2)†
Fruit 1.6 (1.0) 1.6 (1.1) 2.6 (1.5) 1.8 (1.2) 156.6 (542.9) 57.5 (295.7) 99.1 (80.8 to 117.5)†
Vegetables 2.0 (1.1) 2.0 (1.1) 2.6 (1.5) 2.1 (1.2) 60.1 (168.3) 22.7 (120.9) 37.4 (31.1 to 43.7)†
Grains 4.7 (2.5) 4.8 (2.5) 4.6 (2.5) 4.0 (2.2) 15.5 (80.6) −2.0 (123.5) 17.6 (12.7 to 22.4)†
Vitamin E, mg/d 9.1 (5.7) 9.1 (5.5) 7.3 (5.4) 8.1 (5.0) −9.1 (72.0) 2.0 (63.8) −11.2 (−14.2 to −8.2)†
Dietary folate equivalent, µg/d 541.6 (421.1) 541.2 (423.4) 872.4 (480.8) 815.2 (492.7) 133.5 (210.0) 116.7 (192.4) 16.9 (7.8 to 25.9)†
Biomarkers
Total cholesterol, mg/dL‡ 224.0 (36.5) 224.2 (39.2) 214.1 (35.3) 216.6 (35.9) −3.6 (14.0) −2.1 (13.6) −1.5 (−2.9 to −0.1)§
Triglycerides, mg/dL‡ 155.8 (85.7) 158.5 (87.2) 161.2 (106.6) 159.6 (76.3) 8.9 (41.4) 8.3 (40.6) 0.6 (−3.5 to 4.6)
Total carotenoids, µg/mL‡ 0.7 (0.4) 0.7 (0.4) 0.7 (0.4) 0.6 (0.4) 6.7 (49.5) 1.1 (47.2) 5.7 (0.8 to 10.5)§
-Tocopherol, µg/mL‡ 2.2 (1.4) 2.2 (1.4) 1.6 (1.4) 1.7 (1.3) −21.7 (52.8) −5.2 (102.2) −16.5 (−24.4 to −8.7)†
Weight, kg 76.8 (16.6) 76.7 (16.5) 75.7 (17.1) 76.7 (16.8) −0.7 (11.0) 1.2 (11.5) −1.8 (−2.1 to −1.6)†
SI conversions: To convert total cholesterol to mmol/L, multiply by 0.0259; to convert triglycerides to mmol/L, multiply by 0.0113.
*Dietary data were estimated using a food frequency questionnaire.
†Difference is significant at P.001 by 2-sample t test using log-transformed values.
‡Measured in a 5.8% subsample (n = 2816). Means (SDs) are weighted by race/ethnicity using the racial/ethnic distribution of participants randomized to the entire trial. Tests of differ-
ences between the randomization groups were performed on the weighted means (SDs).
§Difference is significant at P.05 by 2-sample t test using log-transformed values.
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in other hypothesized dietary risk fac-
tors for colorectal cancer, including bio-
markers. Differential changes at 3 years
were expressed as a percentage of ini-
tial mean.
Analyses were carried out using SAS
statistical software, version 9.1 (SAS In-
stitute Inc, Cary, NC). P.05 was con-
sidered statistically significant for all
analyses.
RESULTS
A total of 19 541 women (40%) were
assigned to the intervention group and
29 294 (60%) were assigned to the com-
parison group. The last intervention ses-
sion was held in August 2004, and end
points were accrued to the study
through March 2005. Mean length of
follow-up was 8.1 (SD, 1.7) years
(maximum, 11.2 years).
Baseline Characteristics
Colorectal cancer risk characteristics
were very similar in the 2 study groups,
including age, self-reported race/
ethnicity, education, family history of co-
lorectal cancer, prior colorectal cancer
screening, alcohol use, and mean in-
take of energy, fat, fiber, red meat, veg-
etables and fruits, grains, calcium, and
folate (TABLE 1). There were small im-
balances in 3 characteristics: reported use
of aspirin at baseline with respect to both
frequency(P=.03)andduration(P=.01),
proportion of women randomized to the
various groups in the hormone therapy
trials (P=.05), and proportion of women
subsequently joining the randomized
trial of calcium and vitamin D supple-
mentation (P.001).
Dietary Behavior Change
By the end of the first year, the differ-
ence in percentage of energy from fat
between the comparison group and the
interventions groups was 10.7%
(FIGURE 2). During the entire interven-
tion period, the differential reduction
in percentage of energy from fat was
about 70% of the design goals of the
trial. Relatively few women met the di-
etary target of 20% energy from fat
(31.4% at year 1 and 14.4% at year 6).
Reductions in saturated fat consump-
tion and increases in fruit and veg-
etable servings and servings of grain
(Figure 2) were statistically signifi-
cant by 1 year. The intervention was
also associated with statistically signifi-
cant increases in dietary intake of fo-
late and in plasma total carotenoids and
reductions in reported red meat con-
sumption, total vitamin E intake,
weight, serum cholesterol, and plasma
-tocopherol (TABLE 2).
Table 3. Annualized Incidence Rate of Outcomes in Intervention vs Comparison Groups
Outcomes
Intervention,
No. (%)
(n = 19 541)*
Comparison,
No. (%)
(n = 29 294)*
Hazard Ratio
(95% CI)†
Invasive colorectal cancer‡ 201 (0.13) 279 (0.12) 1.08 (0.90-1.29)
Colon cancer 153 (0.10) 218 (0.09) 1.05 (0.85-1.30)
Proximal colon (C18.0, C18.2-C18.5)§ 106 (0.07) 127 (0.05) 1.25 (0.96-1.61)
Distal colon (C18.6, C18.7)§ 41 (0.03) 76 (0.03) 0.86 (0.56-1.19)
Rectal cancer 50 (0.03) 67 (0.03) 1.11 (0.77-1.61)
Rectosigmoid junction (C19.9)§ 17 (0.01) 21 (0.01) 1.18 (0.62-2.23)
Rectum (C20.9)§ 33 (0.02) 47 (0.02) 1.06 (0.68-1.65)
Other (overlapping lesions/unknown/missing) 8 (0.01) 12 (0.01) ND
Colorectal cancer mortality 47 (0.03) 56 (0.02) 1.26 (0.85-1.85)
Incidence of polyps/adenomas¶ 3402 (2.16) 5567 (2.35) 0.91 (0.87-0.95)
Total cancer incidence 1946 (1.24) 3040 (1.28) 0.97 (0.89-1.05)
Total cancer mortality 436 (0.28) 690 (0.29) 0.96 (0.90-1.01)
Global index# 2051 (1.30) 3207 (1.35) 0.95 (0.90-1.01)
Total mortality 950 (0.60) 1454 (0.61) 0.97 (0.89-1.05)
Abbreviations: CI, confidence interval; ND, analysis not done because the events were not part of the major subdivi-
sions of invasive colorectal cancer.
*Mean follow-up time for both groups was 8.1 (SD, 1.7) years.
†Cox regression models stratified according to age group, prior colorectal cancer, and hormone therapy study par-
ticipation; calcium and vitamin D study participation was adjusted as a time-dependent variable.
‡Earliest event from all possible subsites.
§C18 indicates cecum; C18.2, ascending colon, right colon; C18.3, hepatic flexure of colon; C18.4, transverse colon;
C18.5, splenic flexure of colon; C18.6, descending colon, left colon; C18.7, sigmoid colon; C19.9, rectosigmoid
junction; C20.9, rectum, not otherwise specified.
All colorectal cancer–related mortality, with or without prior reporting of colorectal cancer.
¶Self-reported outcomes only.
#Global index is defined as the first of invasive breast cancer, any colorectal cancer, coronary heart disease, or death
due to other causes.
Figure 3. Kaplan-Meier Estimated Cumulative Hazards for Invasive Colorectal Cancer
(N=48 835)
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Colorectal Cancer Risk
and Other Clinical Outcomes
As of March 31, 2005, there were 201
cases of invasive colorectal cancer
(0.13% per year) in the intervention
group and 279 (0.12% per year) in
the comparison group, similar to
national statistics for women in this
age range (0.12%).19 The WHI low-fat
eating pattern intervention did not
reduce the risk of invasive colorectal
cancers (HR, 1.08; 95% CI, 0.90-1.29)
(TABLE 3). Adjustment for the small
imbalance in aspirin use did not alter
these results (HR, 1.08; 95% CI, 0.90-
1.29). The cumulative hazards for
colorectal cancer in the 2 groups were
very similar over follow-up time
(weighted P=.29) (FIGURE 3). There
was no evidence of a time trend for
invasive colorectal cancer in second-
ary analyses (P=.60 for trend), with
HRs in the early, middle, and late
periods of 1.24 (95% CI, 0.85-1.81),
0.91 (95% CI, 0.68-1.22), and 1.19
(95% CI, 0.89-1.60), respectively.
There was no evidence of reduced
risk for any category of colorectal can-
cer outcome associated with the inter-
vention. The estimated intervention ef-
fects in proximal and distal colon cancer
were somewhat different (HRs, 1.25 vs
0.86; P=.07 from likelihood ratio test),
but there was no other evidence of dif-
ferential effect by colorectal cancer sub-
site. None of the HRs for total cancer
incidence, total cancer mortality, global
index, or total mortality were statisti-
cally significant. The annualized inci-
dence rates of colon polyps or adeno-
mas (self-report) were lower in the
intervention group than in the com-
parison group (2.16% vs 2.35%, respec-
tively; HR, 0.91; 95% CI, 0.87-0.95). No
differences were seen between groups
for tumor characteristics (TABLE 4).
Colorectal clinical examination rates
were similar between the intervention
groups (FIGURE4). There were small dif-
ferences in the percentage of women
with no colonoscopy or sigmoidos-
copy during follow-up (45.7% for in-
tervention vs 44.1% for comparison;
P=.04). Overall, 10.6% in the interven-
tion group and 9.9% in the compari-
son group had neither colon nor rec-
tal screenings during follow-up
(P=.30).
Subgroup Analyses
Among the 23 subgroups examined, only
the interactions with aspirin use and the
composite variable of combined hor-
mone use (personal use at baseline or
randomization to active estrogen plus
progestin) were significant at the .01 level
(FIGURE 5). Although the risk of colon
cancer increased with age, there was no
interaction of intervention with age at
baseline (P= .18). Intervention HRs
were not significantly different among
the 4 different racial/ethnic groups with
sufficient numbers of events (P=.78).
The estimated intervention effect was
lower in baseline high-dose aspirin us-
ers compared with that in nonusers
(P= .01); however, the higher inci-
dence observed (0.19%) in this sub-
group of comparison women is an
anomaly, suggesting that other factors
may be relevant. No interaction was
seen with duration of aspirin use, statin
use, or nonaspirin nonsteroidal anti-
Table 4. Annualized Incidence Rate of Invasive Colorectal Cancer by Tumor Characteristics in
Intervention vs Comparison Groups
Variables
No. (%)
Hazard Ratio
(95% CI)*
Intervention
(n = 19 541)
Comparison
(n = 29 294)
Histology
8140/8210/8220/8261/8263
Adenocarcinoma†
171 (0.11) 226 (0.09) 1.13 (0.93-1.38)
8480/8481 Mucinous† 22 (0.01) 41 (0.02) 0.80 (0.48-1.34)
Other (8010/8020/8490/missing data)† 8 (0.01) 12 (0.01) ND
SEER stage
Localized 93 (0.06) 119 (0.05) 1.17 (0.89-1.53)
Regional 77 (0.05) 113 (0.05) 1.02 (0.76-1.36)
Distant 25 (0.02) 35 (0.01) 1.08 (0.64-1.80)
Missing data 6 (.01) 12 (0.01) ND
Tumor grade
Well differentiated 19 (0.01) 23 (0.01) 1.25 (0.68-2.29)
Moderately differentiated 117 (0.07) 173 (0.07) 1.01 (0.80-1.28)
Poorly differentiated/anaplastic 46 (0.03) 58 (0.02) 1.19 (0.81-1.76)
Missing data 19 (0.01) 25 (0.01) ND
Tumor size, cm
3 35 (0.02) 41 (0.02) 1.26 (0.80-1.98)
3-3.9 26 (0.02) 48 (0.02) 0.81 (0.50-1.30)
4-5.9 47 (0.03) 58 (0.02) 1.22 (0.83-1.80)
6 30 (0.02) 54 (0.02) 0.82 (0.52-1.28)
Missing data 63 (0.04) 78 (0.03) ND
Lymph node involvement
No 121 (0.08) 157 (0.07) 1.15 (0.91-1.46)
Yes 65 (0.04) 94 (0.04) 1.04 (0.76-1.43)
Missing 15 (0.01) 28 (0.01) ND
No. of positive lymph nodes
0 109 (0.07) 148 (0.06) 1.10 (0.86-1.41)
1-2 32 (0.02) 44 (0.02) 1.10 (0.70-1.74)
3 27 (0.02) 45 (0.02) 0.90 (0.56-1.46)
Unknown/missing data 33 (0.02) 42 (0.02) ND
Abbreviations: CI, confidence interval; ND, analysis not done because the events were not part of the major histological
groupings or were related to missing codes for stage, grade, etc; SEER, Surveillance, Epidemiology, and End Re-
sults.
*Cox regression models stratified according to age group, prior colorectal cancer, and hormone therapy study par-
ticipation; calcium and vitamin D study participation was adjusted as a time-dependent variable. None of the carci-
noma characteristics had significant interactions with intervention effect by 2 test on the case frequencies (P.05).
†Histology code details19: 8140, adenocarcinoma, not otherwise specified ; 8210, adenocarcinoma in adenomatous
polyp; 8220, adenocarcinoma in adenomatous polyposis coli; 8261, adenocarcinoma in villous adenoma; 8263, ad-
enocarcinoma in tubulovillous adenoma; 8480, colloid (mucinous); 8481, mucin-secreting; 8010, carcinoma; 8020
carcinoma, undifferentiated, not otherwise specified; 8490, signet-ring cell.
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inflammatory drug use at baseline, or
with aspirin use during follow-up, ex-
amined as a time-dependent covariate.
Using data from the baseline 4-day
food record of cases, no interactions
with intervention effect were found with
energy intake, percentage of energy
from fat, percentage of energy from
saturated fat, or dietary fiber. Simi-
larly, using baseline food frequency
questionnaire data, there were no in-
teractions with servings of vegetables
and fruits (FIGURE 6), of red meat, or
of grains or folate intake. The interac-
tion test with baseline alcohol con-
sumption was not significant (P=.09)
and did not appreciably change when
folate intake was considered.
Further Analyses
To explore the effect of nonadherence to
trial activities, a Cox regression model
was fit censoring follow-up for a partici-
pant when she first became nonadher-
ent (did not attend the annual clinic visit
or, for intervention women, completed
50% or fewer intervention sessions in a
given year). Inverse censoring probabil-
ity weights, derived from Cox regres-
sion models of 18 baseline variables
(demographic, dietary, psychosocial,
family history of colorectal cancer, physi-
cal activity, body mass index, alcohol
consumption, multivitamin use, and ran-
domization into the hormone therapy
trial) for intervention and comparison
groups separately, were used to adjust for
the imbalance created by the adherence
censoring.25
Adherence rates from these models
were 85%, 75%, and 66% at years 3, 6,
and 9, respectively, among compari-
son women and 61%, 37%, and 25%
among intervention women. The dif-
ference between adherent interven-
tion vs adherent comparison women in
percentage of energy from fat (from the
food frequency questionnaire) was
12.1%, 11.4%, 10.4%, and 9.5% at years
1, 3, 6, and 9. The HR for colorectal can-
cer from the inverse probability–
weighted analysis was 1.09 (95% CI,
0.88-1.36). Exploratory analyses us-
ing other adherence measures did not
appreciably change the interpretation.
COMMENT
An intervention aimed toward a low-fat
eating pattern did not reduce colorectal
cancer risk in postmenopausal women.
Despite a significant change in fat in-
take and increases in vegetable, fruit, and
grain consumption, the intervention haz-
ard ratio is in the direction of an in-
creased risk. There were no substantial
differences in tumor characteristics or in
rates of bowel screening between groups.
Although self-reported incidence of co-
lorectal polyps or adenomas was lower
in the intervention group, no evidence
of a trend toward lower colorectal can-
cer risk with time in the intervention
group was observed over the mean 8.1-
year study period.
These findings are consistent with the
findings from the Polyp Prevention
Trial,31 a secondary prevention trial of
polyp recurrence, which had a similar
goal for fat, fruit, and vegetable intake but
also included a goal of 18 g/1000 kcal of
dietary fiber.32 ThePolypPreventionTrial
observed no effect on polyp recurrence
in the 2079 participants followed up for
4 years.32 A small trial in Toronto, On-
tario, of high fiber and low fat showed
no effect on recurrence of neoplastic pol-
yps, but, within an intensive counsel-
ing subgroup, concentrations of fecal bile
acids appeared to be reduced.33 A small
factorial trial in Australia of a low-fat in-
tervention, -carotene supplementa-
tion, or wheat bran supplementation
found no reduction in recurrence rates
of adenomas but suggested that the com-
bination of low fat and wheat bran re-
duced the transition from smaller to
larger adenomas.34
Since the WHI Dietary Modification
Trial was designed, the hypothesized re-
lationship between dietary fat and risk
of colorectal cancer has been ques-
tioned.35 More recently, higher red meat
consumption has been associated with
increasedcolorectal cancer risk,23,36-39 par-
ticularly in the distal colon.23 The puta-
tive mechanism may be related to heme,
the iron carrier of red meat, rather than
to its fat content.23 In the WHI, the di-
etary intervention reduced red meat con-
sumption (Table 2), with no apparent
overall benefit on colorectal cancer risk
but, perhaps, some shift in risk in distal
vs proximal colon cancers.
Mixed support exists for an influence
ofvegetablesandfruitsoncolorectal can-
cer risk.37,40-42 Some of the antioxidants
they contain have not proved effica-
cious in reducing colorectal adenomas
or preventing incident colorectal can-
Figure 4. Bowel Examinations by Dietary Intervention vs Comparison Group and Follow-up
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cer inrandomizedtrials.43-45 Regularcon-
sumption of alcohol has been associ-
ated with elevated risk of colorectal
cancer in some prospective studies, par-
ticularly among persons with low folate
status.46 This pattern was not found in
the comparison group of this study.
Observations in East Africa by Burkitt47
led to the hypothesis that very high fiber
reduces colorectal cancer risk. This has
mixed support from observational stud-
ies48-50 and polyp and adenoma recur-
rence trials.31,33,34,51,52 A European trial
found an adverse effect of soluble fiber
on colorectal adenoma recurrence,51
Figure 5. Invasive Colorectal Cancer Hazard Ratios and Annualized Incidence by Baseline Demographic and Medical History Characteristics
No. of Cases of Colorectal Cancer
(Annualized Percentage) Favors
Intervention
Favors
Comparison†
101.00.1
Hazard Ratio (95% Confidence Interval)
Intervention Comparison
P Value
for Interaction∗
.18
Age at Enrollment, y
39 (0.06) 66 (0.07)50-59
67 (0.27) 70 (0.19)70-79
95 (0.13) 143 (0.13)60-69
.78
Race/Ethnicity
165 (0.13) 229 (0.12)White
23 (0.14) 30 (0.12)Black
5 (0.09) 11 (0.13)Hispanic
0 0American Indian
4 (0.12) 3 (0.06)Asian or Pacific Islander
4 (0.15) 6 (0.15)Unknown/Other
.36
26 (0.14)
151 (0.12)
44 (0.16)
200 (0.11)
First-Degree Relative
With Colorectal Cancer
Yes
No
.84
81 (0.14)
45 (0.11)
46 (0.13)
94 (0.11)
67 (0.11)
74 (0.14)
Body Mass Index‡
25-29
<25
30-35
29 (0.12) 44 (0.13)>35
.017 (0.11)
170 (0.13)
24 (0.11)
11 (0.11)
203 (0.11)
65 (0.19)
Aspirin Use
<325 mg/d
None
≥325 mg/d
.6539 (0.10)
117 (0.15)
45 (0.12)
64 (0.10)
140 (0.13)
75 (0.12)
Randomization
Randomized to Calcium and Vitamin D Active
Not Randomized to Calcium and Vitamin D
Randomized to Calcium and Vitamin D Placebo
.11
30 (0.22)
110 (0.17)
11 (0.15)
33 (0.16)
139 (0.14)
9 (0.08)
Hormone Use at Baseline
Past User: Estrogen Alone
Never User
Past User: Estrogen Plus Progestin
4 (0.29) 3 (0.18)Past User: Both
29 (0.07) 54 (0.09)Current User: Estrogen Alone
17 (0.06) 40 (0.09)Current User: Estrogen Plus Progestin
.16
15 (0.30)
160 (0.12)
8 (0.15)
11 (0.13)
219 (0.11)
12 (0.14)
Randomized to Hormone Therapy Trials
Randomized to Estrogen Alone Active
Not in Either Hormone Therapy Trial
Randomized to Estrogen Alone Placebo
5 (0.06) 13 (0.11)Randomized to Estrogen Plus Progestin Active
13 (0.18) 24 (0.23)Randomized to Estrogen Plus Progestin Placebo
.92
157 (0.14)
44 (0.10)
216 (0.13)
63 (0.09)
Baseline Current Estrogen Alone User or Randomized
to Estrogen Alone Trial Active Arm
No
Yes
.01
179 (0.15)
22 (0.06)
226 (0.13)
53 (0.09)
Baseline Current Estrogen Plus Progestin User
or Randomized to Estrogen Plus Progestin Active
Treatment Group
No
Yes
Error bars indicate 95% confidence intervals.
*Interaction test from likelihood ratio test (factors on the continuous scale were tested as continuous variables when possible.
†Cox regression models stratified according to age group, hormone therapy study participation, and prevalence condition; calcium and vitamin D study participation
was adjusted as a time-dependent variable.
‡Body mass index was calculated as weight in kilograms divided by the square of height in meters.
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while an Arizona trial found no effect of
wheat bran supplement on colorectal
adenoma recurrence.52 Our study is con-
sistent with lack of association in that
women in the intervention group mod-
estly increased their fiber (Table 2) with
no apparent benefit over 8.1 years of fol-
low-up.
The observed interactions between the
intervention and baseline aspirin use,
and between intervention and use of
combined hormone therapy, are con-
sistent with synergistic effects of a low-
fat dietary pattern and these poten-
tially protective agents. However, given
the large number of interactions tested,
these findings could also have oc-
curred by chance.
While the trial was ongoing, na-
tional dietary recommendations moved
from recommending less than 30% of
energy from fat intake through 1997 to
25% to 35% of energy from fat in 2002.53
From National Health and Nutrition
Examination Survey (NHANES) data,
in 1977, women reported consuming
40.5% of their energy from fat, while
in 1987, the average was only 35.9%,54
and in 2000, the average was 33%
(NHANES 1999-2000). Organiza-
tions including the National Cancer In-
stitute, American Cancer Society, and
Institute for Cancer Prevention have
recommended both lower fat intake and
increased vegetable and fruit use.55,56
One explanation for a lack of inter-
vention effect on colorectal cancer could
be that the intervention did not achieve
a large enough difference between the
intervention and comparison groups.
Although the changes achieved were
substantial, and likely as large as could
be achieved in a trial of free-living in-
dividuals, they fell short of the origi-
nal design assumptions based on the
Women’s Health Trial studies.27 Using
food frequency data, the WHI inter-
vention on average achieved only about
Figure 6. Invasive Colorectal Cancer Hazard Ratios and Annualized Incidence by Baseline Dietary Factors
No. of Cases of Colorectal Cancer
(Annualized Percentage) Favors
Intervention
Favors
Comparison†
101.00.1
Hazard Ratio (95% Confidence Interval)
Intervention Comparison
P Value
for Interaction∗
.29
.61
.46
.76
.95
.09
54
50
53
69
70
58
Dietary Energy, kcal/d‡
1391.8-<1663.6
<1391.8
1663.6-<1958.7
35 72≥1958.7
53
42
50
65
59
74
Dietary Energy From Fat, %‡
27.9-<32.3
<27.9
32.3-<36.8
47 71≥36.8
52
32
54
72
52
76
Dietary Enery From Saturated Fat, %‡
8.5-<10.3
<8.5
10.3-<12.2
54 69≥12.2
55
53
53
87
66
71
Dietary Fiber, g/d‡
13.0-<16.6
<13.0
16.6-<20.6
31 45≥20.6
51 (0.13)
53 (0.14)
47 (0.12)
66 (0.10)
72 (0.12)
68 (0.11)
Combined Vegetables/Fruits, Medium Servings/d§
2.3-<3.3
<2.3
3.3-<4.6
48 (0.12) 72 (0.12)≥4.6
44 (0.16)
23 (0.15)
100 (0.10)
56 (0.13)
34 (0.15)
164 (0.11)
Alcohol Intake
Past Drinker
Never Drinker
<1 Drink/d
30 (0.20) 23 (0.10)≥1 Drink/d
Error bars indicate 95% confidence intervals.
*Interaction test from likelihood ratio test (factors on the continuous scale were tested as continuous variables when possible.
†Cox regression models stratified according to age group, hormone therapy study participation, and prevalence condition; calcium and vitamin D study participation
was adjusted as a time-dependent variable.
‡Case-only analysis using 4-day food record data; no annualized rates available.
§Data are from food frequency questionnaire.
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70% of the designed reduction in fat.
If design assumptions are revised to take
into account this departure from goal,
the predicted HR would have been 0.86,
an effect size excluded by these re-
sults. The power to detect this effect size
under the observed comparison group
incidence rate and the achieved adher-
ence is approximately 40%.
Whether greater adherence, inter-
vention of longer duration, or initia-
tion of change at an earlier age would
influence colorectal cancer risk re-
main unanswered questions. The self-
reported first occurrence of polyps or
adenomas was lower in dietary inter-
vention women, suggesting that longer
follow-up (currently planned) may re-
veal delayed benefit in favor of the in-
tervention. Yet no time trends regard-
ing colorectal cancer risk over 8 years
of follow-up have been seen. To the ex-
tent that the WHI Dietary Modifica-
tion Trial intervention addressed the
recommendations from national orga-
nizations, the current results suggest
that changing dietary patterns to meet
these recommendations in mid to late
life will have limited or no benefit in
preventing colorectal cancers in post-
menopausal women.
The strengths of this study are its ran-
domized design, long-term follow-up,
large numbers of participants, diver-
sity of race/ethnicity and socioeco-
nomic status, and high retention rate.
The limitations of this study include not
attaining intervention goals as de-
signed for reducing fat intake or achiev-
ing large separation from the compari-
son group in increased fruit, vegetable,
or grain intake. Thus the potential in-
tervention effect of the WHI low-fat di-
etary pattern may be underestimated.
Furthermore, there was no study-
specified colonoscopy, nor was there
systematic screening for adenomatous
polyps; hence, the incidence of both co-
lorectal cancer and polyps or adeno-
mas would be underestimated.
In conclusion, there is no evidence
that a low-fat dietary pattern interven-
tion reduces colorectal cancer risk over
an average of 8.1 years of follow-up.
Evidence from this study, along with
that from polyp prevention trials,
strongly suggests that lowering di-
etary fat intake and increasing fruit, veg-
etable, and fiber intake in mid to late
life cannot be expected to reduce the
risk of colorectal cancer in this length
of time.
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